Serum insulin-like growth factor 1 (IGF-1) in multiple sclerosis: relation to cognitive impairment and fatigue

Table 3 Relationship between serum IGF-1 levels and clinical scales and clinical parameters as well as treatment among multiple sclerosis patients

Variable		Serum IGF levels (M ± SD)	P value
Cognitive affection (MoCA scale score)
> 26		189 ± 22.96	< 0.001*
≤ 26		91.96 ± 21.20	< 0.001*
Fatigue scale (MFIS)
≥ 38		103.09 ± 38.59	< 0.001*
< 38		180.38 ± 35.74	< 0.001*
EDSS
0–5.5		176.2 ± 37.26	0.001*
6–9.5		89.2 ± 22.05	0.001*
Disease course
Progressive	12	81.4 ± 22.03	< 0.001*
Relapsing remittent	34	155.4 ± 49.06	< 0.001*
Disease duration
≤ 5 years		153.68 ± 51.94	0.004*
> 5 years		107.4 ± 43.47	0.004*
Specific treatment
Yes		159.89 ± 49.12	1.0
No		124.54 ± 52.63	1.0

*Significant
EDSS expanded disability status scale, IGF-1 insulin-like growth factor 1, MFIS modified fatigue impact scale, MoCA Montreal cognitive scale